Unusual 11 Mid-Day Movers 10/13: (AEZS) (OCUL) (CTRV) High; (FLDM) (APTO) (FLKS) Low

October 13, 2016 12:49 PM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Fluidigm Corporation (Nasdaq: FLDM) 27.0% LOWER; announced preliminary revenue for the third quarter ended September 30, 2016. Estimated total revenue for the third quarter of 2016, based on management’s preliminary analysis, was approximately $22.2 million. (The consensus was at $29.3 million.)

Aptose Biosciences Inc. (Nasdaq: APTO) 21.0% LOWER; received a response from the U.S. Food and Drug Administration (FDA) regarding the clinical hold of Aptose’s Phase 1b clinical trial of APTO-253 in patients with hematologic cancers requesting additional information and informing Aptose that the hold would not be removed until this information is submitted and reviewed. The FDA response to Aptose focused exclusively on the request to provide the FDA with complete Chemistry, Manufacturing and Control (CMC) information on the final GMP drug substance and drug product intended for the clinic.

Flex Pharma, Inc. (Nasdaq: FLKS) 20.4% LOWER; provided a nocturnal leg cramp (NLC) regulatory and clinical update for FLX-787, a topically-acting, selective transient receptor potential (TRP) ion channel agonist, which the Company is evaluating for the treatment of nocturnal leg cramps (NLC), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and other disorders.

Aeterna Zentaris Inc. (Nasdaq: AEZS) 16.2% HIGHER; Aeterna Zentaris continuing higher above the $4 level following a strong run on Wednesday. Yesterday, the company and Specialised Therapeutics Asia announced the signing of an exclusive license agreement for the Company’s lead investigational anti-cancer compound, Zoptrex (zoptarelin doxorubicin), for the territories of Australia and New Zealand.

Ocular Therapeutix, Inc. (Nasdaq: OCUL) 16.2% HIGHER; announced that it has entered into a strategic collaboration, option and license agreement with Regeneron Pharmaceuticals, Inc. Ocular and Regeneron will collaborate on the development of a sustained release formulation of the vascular endothelial growth factor (VEGF) trap aflibercept for the treatment of wet age-related macular degeneration (wet AMD) and other serious retinal diseases.

ContraVir Pharmaceuticals, Inc. (Nasdaq: CTRV) 15.7% HIGHER; reported positive interim data for CMX157, the Company's highly potent prodrug of tenofovir, from its ongoing Phase 2a multiple ascending dose clinical study. The head-to-head study is the first evaluation of CMX157 in HBV patients, and directly compares CMX157 to tenofovir disoproxil fumarate (TDF, Gilead's Viread®) in chronically infected hepatitis B (HBV) patients.

Covenant Transportation Group, Inc. (Nasdaq: CVTI) 15.1% LOWER; said it expects to report net income in the range of $2.1 million to $3.2 million, or $0.12 to $0.17 per diluted share, for the third quarter of 2016. (The Street consensus is at $0.25.)

TG Therapeutics, Inc. (Nasdaq: TGTX) 14.3% LOWER; announced that it has filed with the FDA an amended protocol for the GENUINE Phase 3 trial. For more color, click here.

Lindsay Corp. (NYSE: LNN) 12.6% HIGHER; reported Q4 EPS of $0.73, $0.30 better than the analyst estimate of $0.43. Revenue for the quarter came in at $132.9 million versus the consensus estimate of $113.38 million. The backlog of unshipped orders at August 31, 2016 was $50.7 million compared with $48.0 million at August 31, 2015

Ulta Beauty (Nasdaq: ULTA) 11.0% HIGHER; updated Q3 guidance. For the third quarter of fiscal 2016, the Company now expects comparable sales, including e-commerce sales, to increase 14% to 15%, compared to previous guidance of 11% to 13%. The Company reported a comparable sales increase of 12.8% in the third quarter of fiscal 2015. Income per diluted share for the third quarter of fiscal 2016 is estimated to be in the range of $1.35 to $1.38, compared to prior guidance of $1.25 to $1.30. The Company reported income per diluted share for the third quarter of fiscal 2015 of $1.11. (The Street sees Q3 EPS of $1.30.)

Five Star Quality Care, Inc. (Nasdaq: FVE) 10.6% HIGHER; Senior Star Management Company issued a statement in response to the $3.00 per share tender offer for up to 10,000,000 shares of Five Star Quality Care commenced on October 6, 2016 by ABP Acquisition LLC, an entity controlled by Barry M. Portnoy and Adam D. Portnoy. Senior Star announced that it intends to commence a tender offer through an affiliated entity for up to 10,000,000 shares of the Company's common stock in the coming days at a price of $3.45 per share in cash and urges FVE shareholders take no action at this time in response to the Portnoy's inferior $3.00 per share offer.

To get this report daily visit http://www.streetinsider.com/entities/Unusual+11+Mid-Day+Movers.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Special Reports

Related Entities

Unusual 11 Mid-Day Movers

Add Your Comment